The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Breast Cancer
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
-
CHS Grandview, Birmingham, Alabama, United States, 35243
Providence Alaska Medical Center, Anchorage, Alaska, United States, 99508
Arizona Oncology Associates, PC, Phoenix, Arizona, United States, 85006
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States, 85704
Adventist Health - Bakersfield, Bakersfield, California, United States, 93301
Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States, 92262
North Valley Breast Clinic, Redding, California, United States, 96001
UCSF Breast Care Center, San Francisco, California, United States, 94158
Valley Breast Care, Van Nuys, California, United States, 91405
Rocky Mountain Cancer Centers, Aurora, Colorado, United States, 80012
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Agendia,
William Audeh, MD, STUDY_DIRECTOR, Agendia, Inc.
Joyce O'Shaughnessy, MD, PRINCIPAL_INVESTIGATOR, Texas Oncology - Baylor Charles A. Sammons Center
2037-12